Table 2.

Grade 3 and 4 hematologic adverse events summarized from the included five trials.

Grade 3/4 adverse events	Study	Docetaxel		Paclitaxel
		Incidence (%)	Regimen	Incidence (%)	Regimen
Neutropenia	Jones et al.	93.3	100 mg/m2 Q3W	54.5	175 mg/m2 Q3W
	Cassier et al.	27.8	75 mg/m2 Q3W	7.8	175 mg/m2 Q3W
	Kelly et al.	15.4	75 mg/m2 Q3W	0.6	80 mg/m2 QW
	Watanabe et al.	6.9	75 mg/m2 Q3W	1.9	175 mg/m2 Q3W
Leukopenia	Cassier et al.	12.5	75 mg/m2 Q3W	3.9	175 mg/m2 Q3W
	Watanabe et al.	3.1	75 mg/m2 Q3W	0.4	175 mg/m2 Q3W
Febrile Neutropenia	Jones et al.	14.9	100 mg/m2 Q3W	1.8	175 mg/m2 Q3W
	Cassier et al.	2.8	75 mg/m2 Q3W	1.3	175 mg/m2 Q3W
	Kelly et al.	4.4	75 mg/m2 Q3W	0.0	80 mg/m2 QW
	Watanabe et al.	8.1	75 mg/m2 Q3W	0.4	175 mg/m2 Q3W
	Swain et al.	9.0	75 mg/m2 Q3W	3.1	175 mg/m2 Q2W
Anemia	Cassier et al.	0.0	75 mg/m2 Q3W	1.3	175 mg/m2 Q3W
	Swain et al.	0.2	75 mg/m2 Q3W	1.6	175 mg/m2 Q2W
Thrombocytopenia	Jones et al.	4.6	100 mg/m2 Q3W	2.8	175 mg/m2 Q3W

Jones et al. did not report incidence of 3% or lesser in either treatment group.

Data of adverse events from Cassier et al. were from Cycle 5-8 in the study, when the patients were combined with doxorubicin.